Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Post-Market Plan Gains Support, But Many Details Still Lacking

This article was originally published in The Gray Sheet

Executive Summary

A diverse set of stakeholders backed FDA’s new proposed national post-market surveillance plan during a series of public meetings last week, but participants warned “the devil is in the details.”

You may also be interested in...

Planning Board Urges FDA To Launch Postmarket Incubator Project

FDA and its collaborators should launch an incubator project with fact-finding activities and pilot programs to help launch a national postmarket surveillance system that builds on Unique Device Identifiers (UDIs), registries, and innovative data capture and analysis strategies, a multi-stakeholder planning board recommends.

Planning Board Proposes Postmarket Device Surveillance Timeline

A planning board created to develop a framework for a new U.S. medical device surveillance system has proposed a seven year plan on how to get the system up and running, which will include creating incentive systems for stakeholders as well as reducing the burden of recording and managing device data.

Regulatory Briefs: MAUDE Replacement; Electronic Source Data Guidance; Social Media Monitoring

The device center plans to replace the MAUDE adverse events database system by the end of the year. Agency issues final guidance on electronic source data in clinical investigations. FDA purchases social media monitoring software to gauge the effectiveness of its online communications. More regulatory news.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts